Glenmark Pharmaceuticals ltd — Capital/Financing Update 2025

Jan 21, 2025

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

January 21, 2025

To, To,

Dy. General Manager The Manager – Listing,

Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd. Plot No. C/1, G Block Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

With reference to the subject mentioned above, kindly find attached media release which is selfexplanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK KUBER VINAYAK KUBER Date: 2025.01.21 08:41:31 +05'30'

Harish Kuber Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [579 x 130] intentionally omitted <==

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

Mahwah, New Jersey, January 21, 2025: Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch[1] of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. Glenmark’s Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.

According to IQVIA[TM] sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market[2] achieved annual sales of approximately $19.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”

---End---

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted more than 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

==> picture [596 x 36] intentionally omitted <==

==> picture [579 x 130] intentionally omitted <==

For more information, please contact

Udaykumar Murthy | corpcomm@glenmarkpharma.com | +91 9960377617

References:

1Glenmark’s Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules is only approved for the indication(s) listed in Glenmark’s approved label.

2Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.

*IQVIA[TM] National Sales Perspectives: Retail & Non-Retail, November 2024

==> picture [596 x 36] intentionally omitted <==